MedTrace Logo

Microdosing Psychedelics to Improve Mood

NCT05259943 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-12-30

No results posted yet for this study

Summary

This trial aims to examine the safety and efficacy of small (2mg) sub-hallucinogenic doses of psilocybin in people with Major Depressive Disorder.

Conditions

Interventions

DRUG

Psilocybin first

Participants will receive 8 doses of 2mg psilocybin.

DRUG

Placebo first

Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin

Sponsors & Collaborators

  • Nikean Foundation

    collaborator UNKNOWN

  • Rotem Petranker

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-15
Primary Completion
2024-12-21
Completion
2025-02-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259943 on ClinicalTrials.gov